Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS; Deemed to be University, Vile Parle West, Mumbai, Maharashtra 400056, India.
Mini Rev Med Chem. 2024;24(20):1847-1855. doi: 10.2174/0113895575293447240424052516.
The National Health and Nutrition Examination Survey (NHANES) carried out a survey between 2007-10 and found that as compared to the general population, the prevalence of anemia in chronic kidney disease (CKD) patients was twice high. Daprodustat is an investigational novel drug for the treatment of renal anemia.
The objective of this study is to provide a comprehensive review of chemistry, synthesis, pharmacology, pharmacokinetic, and bioanalytical methods for the analysis of Daprodustat.
To improve understanding, a review was carried out by creating a database of relevant prior research from electronic sources such as ScienceDirect and PubMed. The methodology is shown in the flowchart of the literature selection process.
The drug was approved in 2020 for therapeutic purposes in Japan. It is a novel drug approved for the treatment of anemia in chronic kidney disease for oral administration. It is intended for adults who have undergone dialysis for a minimum of four months and are experiencing anemia as a result of chronic kidney disease.
This review examines therapeutic, pharmacological, and analytical aspects related to the novel drug Daprodustat.
国家健康和营养检查调查（NHANES）于 2007-10 年期间进行了一项调查，发现与普通人群相比，慢性肾脏病（CKD）患者的贫血患病率高出两倍。达普罗杜司他是一种用于治疗肾性贫血的新型研究药物。
本研究旨在全面综述达普罗杜司他的化学、合成、药理学、药代动力学和生物分析方法。
为了提高理解，通过创建来自 ScienceDirect 和 PubMed 等电子资源的相关先前研究数据库，进行了综述。文献选择过程的流程图显示了该方法。
该药物于 2020 年在日本获得批准用于治疗用途。它是一种新型药物，经批准用于口服治疗慢性肾脏病引起的贫血。适用于至少接受过四个月透析且因慢性肾脏病而出现贫血的成年人。
本综述检查了与新型药物达普罗杜司他相关的治疗、药理学和分析方面。
